OPA1 Dominant Optic Atrophy: Pathogenesis and Therapeutic Targets

Abstract

Dominant optic atrophy (DOA, OMIM 165500) is the most common inherited optic neuropathy (1), with prevalence estimates of 1:12,000 in Denmark (2) and 1:25,000 in North East England (3). Inherited optic neuropathies carry a poor visual prognosis and have a significant detrimental impact on the quality of life, with high rates of psychological distress and great societal costs (4–7). DOA was first described in a British family by Batten in the 19th century (8) and confirmed in larger studies of German families by Jaeger (9) and of Danish families by Kjer (10). These studies demonstrated an autosomal dominant inheritance of isolated optic atrophy, which was clinically and genetically distinct to the maternally inherited Leber hereditary optic neuropathy (LHON, OMIM 535000), (11). Patients with DOA typically suffer an insidious, progressive, and bilateral visual loss starting in early childhood (12). Fundus examination in DOA typically shows temporal pallor of the optic discs (Fig. 1A), corresponding with reduced retinal nerve fiber layer (RNFL) thickness of the papillomacular bundle visible on optical coherence tomography (OCT) imaging (Fig. 1B) (13). OCT angiography shows reduced blood flow in the temporal region of the optic disc (14–16). Macular OCT demonstrates thinning of the ganglion cell layer (Fig. 1C) (17), and perimetry usually shows bilateral central or centrocaecal scotoma (Fig. 1D). These clinical features illustrate that the loss of retinal ganglion cells (RGCs), particularly in the papillomacular bundle, is central to DOA pathogenesis. Approximately 20% of patients with DOA also have multisystemic features (“DOA plus”) such as sensorineural hearing loss, peripheral neuropathy, myopathy, spastic paraplegia, multiple sclerosis–like illness, and chronic progressive external ophthalmoplegia (18,19).FIG. 1.: Typical ophthalmological features in a patient with OPA1-positive DOA. A. Color photograph of the right optic disc in a patient with DOA caused by an OPA1 variant. The disc is diffusely pale with the pallor being more prominent temporally. B. Optical coherence tomography (OCT) imaging of the right optic disc demonstrating loss of the retinal nerve fiber layer particularly temporally. C. Macular OCT of right eye showing substantial RNFL thinning. D. Gray scale of perimetry obtained using a automated 30-2 SITA-Fast (Swedish Interactive Thresholding Algorithm) protocol demonstrating a dense asymmetric scotoma. E, F. Total deviation and pattern deviation of the same visual field. A dense superior scotoma is visible that extends into the inferior hemifield. DOA, Dominant Optic Atrophy; RNFL, Retinal Nerve Fibre Layer.There is marked interfamilial and intrafamilial variability in the severity of the disease, with visual acuities ranging from normal to detection of hand movements only. Half of all DOA patients fail the driving standards and are registered legally blind (12). The source of this variability is not fully understood, and it is likely to be due to a combination of environmental, genetic, and other factors. Although an increasing number of nuclear-encoded gene variants are being identified as the cause of DOA (20), 70%–90% of patients carry variants in the autosomal gene OPA1 (3q29, OMIM 605290) (21,22). The OPA1 gene is large, spanning >90 kbp of genomic DNA (23), and composed of 30 exons (Fig. 2). The transcript (NM_015560.2(OPA1)) is alternatively spliced into 8 different isoforms, and they are translated to Long- (120 kDa) and Short- (80 kDa) forms of OPA1 (24,25). The resulting OPA1 protein is a ubiquitously expressed dynamin-like GTPase protein that has a mitochondrial targeting sequence (MTS, Fig. 2), which facilitates mitochondrial import (26). Once incorporated into the inner mitochondrial membrane, OPA1 regulates a number of mitochondrial functions, including mitochondrial fusion, bioenergetics, mitophagy, and stabilization of the respiratory chain complexes (27). Therefore, DOA is considered to be a mitochondrial disease, despite the autosomal location of the most common causative gene (27). Other genes that cause DOA are also important for mitochondrial function; these genes have been described in recent reviews (20,27,28).FIG. 2.: The OPA1 gene. The human OPA1 gene contains 30 exons. The translated protein consists of a mitochondrial targeting sequence (MTS), transmembrane domains (TM), coiled-coil domains (CC), GTPase, middle domain and a G-protein effector domain (GED).There are more than 500 variants in the OPA1 gene that are likely thought to be pathogenic (23,29). Of these, 28% are missense and mostly in the GTPase domain (29). A further 24% of these genes cause aberrant splicing: 22% cause frameshifts, 15% nonsense, and 7% structural variants (29). Most of these pathogenic variants lead to premature termination of translation, and they are therefore likely to be null alleles, which is consistent with the reduced OPA1 protein concentrations seen in patient-derived fibroblasts (30). Therefore, haploinsufficiency has been proposed to be the primary disease mechanism in OPA1-linked DOA (27). Haploinsufficiency (HI) is a mechanism of dominance where one normal copy of the protein is insufficient to maintain its normal cellular function (Fig. 3) (31). Hence, when there is one null allele, a disease phenotype results. By contrast, dominant-negative (DN) effects are cases where the abnormal protein interferes with the function of the wild-type protein (Fig. 3) (31). An increasing number of OPA1 variants have been shown to result in DN effects. Predominantly, these are missense with a few isolated in-frame splice variants also described, both of which are associated with a more severe phenotype (32,33).FIG. 3.: Haploinsufficiency and dominant negative effects. Haploinsufficiency (HI) occurs when one copy of the gene is a null allele, so it is not expressed at a sufficient level to facilitate normal function of the protein. In OPA1 variants, this results in mitochondrial structural fragmentation, impaired adenosine triphosphate generation, and increased susceptibility to cell death. Therapeutically, this can be addressed by stimulating the expression of the remaining normal allele to protect or rescue mitochondrial function. Dominant negative (DN) effects are manifested when the product of an allele is a protein that interferes with the function of the normal allele. This may require targeted inhibition of the mutant allele in addition to stimulation of the remaining allele to restore normal cell physiology.Understanding the molecular pathogenesis of OPA1-linked DOA may shed light on other diseases too. There is a growing body of evidence linking mitochondrial dysfunction with the neurodegenerative processes contributing to the development and progression of glaucoma (34), Parkinson's disease (35), and late-onset dementias (36), including Alzheimer's disease (37). Therefore, investigating the pathogenesis of DOA provides a powerful model system that has broader significance in advancing our understanding of other major neurodegenerative disorders. Characterization of the unique susceptibility of RGCs in DOA will also aid our understanding of other optic neuropathies, such as glaucoma, and guide the development of targeted therapies. In this perspective, we describe how the clinical presentation of patients with DOA sheds light on the molecular pathogenesis of this disease. We then outline how our understanding of this disease process is being enhanced by the use of increasingly sophisticated model systems, which are revealing potential therapeutic targets. PATHOGENESIS Patients with DOA typically develop insidious bilateral visual loss, generalized dyschromatopsia, and temporal disc atrophy. This points toward a specific dysfunction of RGCs, particularly those constituting the papillomacular bundle. Despite OPA1 being a ubiquitously expressed gene, RGCs appear particularly vulnerable to the effects of genetic variants. This may be because of the intrinsic structural properties of RGCs that make them susceptible to mitochondrial dysfunction. The axons of RGCs are very long—approximately 50 mm in humans (99% of their total cell volume), and they transmit around 15 action potentials per second (38). RGC axons run along the inner surface of the retina, through the lamina cribrosa, along the optic nerve, optic chiasm, and optic tract before synapsing in the lateral geniculate nucleus. The intraocular portion of the RGC is unmyelinated in order to facilitate transparency and retinal light penetration. Therefore, action potentials cannot rely on the energy-conserving saltatory conduction intraocularly, and so, a large amount of adenosine triphosphate (ATP) is required for the management of Na+ and K+ gradients. As a consequence, RGCs have a high metabolic requirement, and they are particularly dependent on mitochondrial aerobic respiration (39). RGC axons are myelinated after passing through the lamina cribrosa, so action potential propagation becomes less energetically demanding outside the eye. Consistent with this, mitochondria are distributed more densely in the intraocular portions of the RGC axons compared with the extraocular portions (40–42). At the lamina cribrosa, there is a transition zone between unmyelinated and myelinated axons; mitochondrial structure here appears to be very dynamic, involving both intramitochondrial and intermitochondrial membrane modifications (27). The RGCs that make up the papillomacular bundle may be particularly vulnerable due to their more limited blood supply (14), increased exposure to oxidative stress generated by passage of light (43), and the relatively smaller caliber of the parvocellular RGC axons, which may physically restrict the transport and maintenance of mitochondria (44). Intrinsically photosensitive RGCs (ipRGCs) appear to be resistant to degeneration in this disease and in many animal models of neuronal damage (45–47). This is consistent with the finding that patients with DOA appear to have preserved physiological diurnal rhythms and pupillary light reflexes (45) because ipRGCs are crucial for circadian entrainment and nonvisual light perception (48–50). The reasons for this are not fully understood but may involve their relatively large diameter axons (44,51) or the expression of neuroprotective genes (52). The ipRGCs also uniquely express melanopsin as their light-sensitive pigment (53,54), but because ipRGCs are still spared in melanopsin knockout models of DOA, melanopsin expression in itself is less likely to be the cause of this resistance (55). Most pathogenic OPA1 variants are haploinsufficient, such as c.2708_2711del, which is the commonest (23). This means that the variant results in a null allele, and the one remaining unaffected allele is insufficient to functionally compensate for this loss. Consistent with this, experimentally knocking out or reducing expression of OPA1 results in mitochondrial structural and functional abnormalities (56–62), whereas overexpression is protective against apoptotic insults (56,63). However, it is believed that supraphysiological overexpression of OPA1 may be toxic (64). Some OPA1 variants exert pathogenic effects through dominant-negative mechanisms. For example, missense and possibly in-frame splicing variants such as c.2356-1G>T, which results in abnormal splicing, could manifest in dominant negativity by affecting OPA1 oligomerization (33). This is important because missense variants and those in the GTPase region of OPA1 generally result in more severe DOA phenotypes and increased chance of extraocular features (19). This distinction is important because different therapeutic approaches are needed for gene therapies (Fig. 3). An understanding of the transcriptional effects of variants is critical before the design of genetic modification strategies such as antisense oligonucleotides (ASOs). For instance, an ASO strategy aiming to upregulate wild-type (WT) transcript expression may not function in the context of a dominant negative variant, for which a knockdown of the disease-causing allele may be more appropriate. Gene therapies are therefore likely to be time consuming and costly to develop, with new variants having to be modeled to ascertain their transcriptional and translational impact. Critical to facilitating this modeling is the establishment of robust disease models, which will be addressed in the next section. MODELING SOLUTIONS Novel disease-causing variants in OPA1 are constantly being reported, highlighting the marked genetic heterogeneity of this particular disease (23,29,65). To facilitate personalized genetic treatments, and to improve our understanding of DOA pathogenesis, a number of modeling solutions have been implemented (Fig. 4).FIG. 4.: Challenges, models, and potential solutions. A therapeutic pipeline for DOA has proven challenging to advance due to the complexity and heterogeneity of the genetic basis of the disease. Various models have been used to better understand the underlying pathophysiology, ranging from in silico hypothesis generation to observational and interventional clinical trials in humans. Each model system has its own advantages and disadvantages, but when used together, exciting new therapeutics can be developed and validated. Current strategies involve the identification of neuroprotective agents that can prevent and restore vision in patients affected with DOA. Gene therapy techniques include the use of viral vectors to replace or correct genes, as well as block and replace gene expression modulation to address dominant negative effects. Finally, cell-based therapies may one day provide a way to regenerate RGCs that have already been lost, although significant hurdles remain. DOA, Dominant Optic Atrophy; RGC, Retinal Ganglion Cell.In silico models have been used to predict the pathogenicity of novel missense variants (23) and the effects of splice site variants (33,66). However, it remains challenging to determine the translational consequences of the predicted transcripts, and in vitro models provide an excellent way to validate these findings (66). As described above, the pathogenesis of DOA is centered around mitochondrial dysfunction, and so cell-based models can be ideal for exploring the haploinsufficiency and dominant-negative effects of OPA1 variants. Patient-derived fibroblasts and mouse embryonic fibroblasts provide convenient in vitro model systems to interrogate patient-specific OPA1 variants and their impact on cellular physiology (33,67,68). However, this method may overlook tissue-specific actions of OPA1. Alternatively, somatic cells may be harvested from patients, for example, from the skin and then reprogrammed to achieve pluripotency. These induced pluripotent stem cells (iPSCs) may be used to create retina organoids (69–72) or specific RGC cultures (73–77). iPSC-derived RGCs also provide an excellent resource for drug screening and development of cellular therapies, in a patient-focused manner, avoiding the ethical issues surrounding the use of embryonic stem cells (78,79). In vivo mouse models have also been used in the field of DOA research (27). Although the mouse Opa1 genetic sequence is 96% similar to the human OPA1, there are important molecular differences. Humans have 8 isoforms of OPA1, whereas mice only have 4 (80). This is important because the correct balance of isoforms has been shown to be important for cellular function (25). This is of particular concern when developing gene therapies. Furthermore, mouse models demonstrate RGC loss primarily due to OPA1 haploinsufficiency, and the insight into the dominant-negative effects of OPA1 variants in humans remains limited (27). One of the strengths of in vivo studies compared with in vitro studies is the ability to assess the effects of OPA1 gene variants on visual function (81). There are well-established behavioral assays to assess vision in mice. However, these should be interpreted within the context of the mouse anatomy in that they do not have a fovea or papillomacular bundle (81), despite the fact that the mouse retina closely resembles the peripheral retina in primates (82). Indeed, it remains unclear whether mice have the same range of RGC subtypes as humans (81). Therefore, mouse models may not recapitulate all aspects of human DOA pathogenesis and visual function. Three major mouse models have been to model OPA1 and and are also model that have been used to DOA pathogenesis and the of have been (27). However, more with a disease-causing variant in OPA1 have been identified at the In these retinal nerve fiber layer thickness and retinal ganglion cell function consistent with a DOA described bilateral optic atrophy in with RGC loss and dysfunction, but a genetic cause has not been A similar in although this may be due to a variant in which is the causative gene in of inherited optic neuropathy These models recapitulate important clinical features of DOA and as translational models to advancing novel therapeutic strategies for this disease. Current and strategies for DOA can be into gene and cell-based therapies (Fig. A major has been on gene therapy because this may of RGCs in DOA. to prevent or damage to RGCs by and other to the progression of the disease. By contrast, cell-based therapies to replace RGCs that have already been neuroprotective strategies that are being considered include which is a of was by the for the of after visual loss The results of a using the mouse model effects and a of but a stabilization and of visual At the time of there are further trials in patients with DOA Current clinical trials for DOA of at Characterization of Dominant Optic of for for Patients Dominant Optic due to OPA1 Gene in Dominant Optic clinical trials as of The clinical for Optic and stem stem Gene therapies have also been developed to neuroprotective However, as most cases of DOA are caused by OPA1 variants, to develop gene therapies have on targeting the haploinsufficiency and dominant-negative contributing to RGC loss. To address haploinsufficiency, gene therapy has been in a mouse This of an human OPA1 into mice Although this of RGCs from the method not provide a way to the level of OPA1 This is a concern because OPA1 overexpression may be to cell function (64). The eye is uniquely in the field of gene therapy because it is and has a relatively of through is an gene therapy that is by to replace the mutant gene and retinal degeneration In was the first in vivo gene therapy to be by the and In results have been seen in gene therapy trials for gene strategy involving may provide an method to the expression of the normal OPA1 allele. are composed of a specific domain and a domain that is to and similar strategies can aspects of In a recent in vitro splicing used to splicing in the of the variant resulting in increased OPA1 expression expression of OPA1 could be with a targeted knockdown of mutant in the of dominant negative variants. For example, can be used to specific which to their by means of the oligonucleotides are smaller usually from 8 to 50 that can also be used to specific for cause and other forms of This strategy has shown potential in studies for and are developing for DOA However, involving or ASO involve to maintain a therapeutic By contrast, be a to correct the disease-causing variant. For example, the use of to the OPA1 in RGCs may provide an to correct variants in further this an in DOA phenotype has been in RGCs from from patients pathogenic OPA1 variants However, will to be to this therapeutic strategy into clinical the used in have a relatively that in vivo use likely only correct a number of In the of an make the of all of the gene required for into a the most important potential to clinical is the of which have been as in effects in or cell genes the and this be by robust screening before human Despite these the eye unique in the field of genetic therapies as a result of its and its of with an The on or degeneration of RGCs in DOA. approaches to replace cells that have already using specific cell from patient-derived which the of However, there are to clinical of this not only the of RGC axons along the optic nerve toward the lateral geniculate but also cell with cell and to the that they restore In there are of genomic and that to be before clinical clinical trials are potential therapies for DOA involving stem cell that may provide a neuroprotective DOA caused by OPA1 variants is the commonest inherited optic neuropathy in the resulting in progressive in and The OPA1 with the of RGCs have not been fully which has limited the therapeutic development for this Although the underlying pathogenesis has an and molecular it is by a common of mitochondrial dysfunction that is to RGCs, resulting in optic nerve degeneration and visual loss. in our understanding of this process have been by a of in in and in vivo models, which is a of exciting novel therapeutic not only for DOA but also more for other optic neuropathies and neurodegenerative diseases that are also thought to be at by impaired mitochondrial

Topics & Concepts